Pozen, which hopes to get its MT 300 drug for migraine relief to market this year, has won another patent related to the drug.

Pozen (Nasdaq: POZN), which has earlier won four patents in the US and two more in Australia, has won a patent that applies to therapeutic packages that will cover the drug as administered by syringe. The patent is the first related to MT 300.

Pozen filed a new drug application to the FDA in December.